Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.
Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.
复制标题
二氧释酶-1 Q192R遗传变异对氯吡格雷反应性和复发性心血管事件的影响：系统评价和荟萃分析。
DOI：
10.1111/j.1538-7836.2012.04756.x
复制
发表时间：
2012-07
期刊：
影响因子：
--
通讯作者：
PON1 Meta-Analysis Group
中科院分区：
文献类型：
--
作者：
Reny JL;Combescure C;Daali Y;Fontana P;PON1 Meta-Analysis Group
A poor biological response to clopidogrel is associated with an increased risk of major cardiovascular ischemic events (MACE). Paraoxonase 1 (PON1) enzyme activity is modulated by the PON1-Q192R variant (rs662) and was recently suggested to be strongly involved in clopidogrel bioactivation, but the influence of the PON1-Q192R variant on the risk of MACE in clopidogrel-treated patients is controversial. To determine whether the PON1-Q192R variant influences clopidogrel biological responsiveness and the risk of MACE in patients treated with clopidogrel. Systematic review and meta-analysis of studies of the association between the PON1-Q192R polymorphism and the biological response to clopidogrel and/or the risk of MACE during clopidogrel administration. Seventeen studies were included. In the 12 studies of the biological response to clopidogrel (n = 5302 patients), there was no significant difference between 192QQ and 192QR + 192RR subjects, whatever the laboratory method used (global mean standardized difference = 0.10 [−0.06; 0.25], P = 0.22). Eleven studies assessed the risk of MACE, four using a case–control design (n = 2739 patients) and seven a prospective design (n = 5353 patients). Overall, MACE occurred in 19% of patients in case–control studies and in 6% of patients in prospective cohort studies, with no significant difference between 192QQ and 192QR + 192RR patients (OR = 1.28 [0.97; 1.68], P = 0.08). Similar results were obtained when study design was taken into account. Heterogeneity was mainly driven by one publication. This meta-analysis suggests that the PON1-Q192R polymorphism has no major impact on the risk of MACE and does not alter the biological response to clopidogrel in clopidogrel-treated patients.
登录
查看更多内容
影响因子：
120.7
作者：
Cayla, Guillaume;Hulot, Jean-Sebastien;Collet, Jean-Philippe
通讯作者：
Collet, Jean-Philippe
影响因子：
6.7
作者：
Farid, N. A.;Payne, C. D.;Salazar, D. E.
通讯作者：
Salazar, D. E.
影响因子：
1.9
作者：
Duval, S;Tweedie, R
通讯作者：
Tweedie, R
影响因子：
20.3
作者：
Hulot, Jean-Sebastien;Bura, Alessandra;Gaussem, Pascale
通讯作者：
Gaussem, Pascale
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N